| Literature DB >> 26680097 |
J Haas1, T Singer1, K Nowak2, J Brust3, U Göttmann1, P Schnülle1, B Krüger1, B K Krämer1, U Benck4.
Abstract
Renal transplantation in HIV-positive patients with end-stage renal disease has in recent years become a successful treatment option. We report two patients who underwent renal transplantation using a combination of basiliximab, calcineurin inhibitors, mycophenolate mofetil (MMF), and steroids with a "non-interacting" antiretroviral combination therapy consisting of stavudine or abacavir, lamivudine, and nevirapine. We observed no acute rejection but a BK polyomavirus infection in both patients. In conclusion, a quadruple immunosuppression with an interleukin 2 receptor antagonist, a calcineurin inhibitor, MMF, and steroids appears to be advisable to prevent high rates of acute rejection, but if possible thereafter immunosuppression should be tapered rapidly (eg, MMF stop, prednisolone dose 5 mg/d). The selection of antiretroviral agents should avoid compounds that interact severely with the immunosuppression used.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26680097 DOI: 10.1016/j.transproceed.2015.09.064
Source DB: PubMed Journal: Transplant Proc ISSN: 0041-1345 Impact factor: 1.066